Achieve Life Sciences (NASDAQ:ACHV) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Achieve Life Sciences (NASDAQ:ACHV) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06), Zacks reports.

Achieve Life Sciences Price Performance

Shares of ACHV opened at $3.06 on Tuesday. The company’s 50-day moving average is $3.23 and its 200-day moving average is $4.06. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. The firm has a market capitalization of $105.23 million, a PE ratio of -2.71 and a beta of 1.67. Achieve Life Sciences has a fifty-two week low of $2.82 and a fifty-two week high of $5.59.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ACHV shares. RODMAN&RENSHAW upgraded shares of Achieve Life Sciences to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw started coverage on Achieve Life Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $12.00 price target for the company. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $15.75.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.